{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:18:40Z","timestamp":1788344320952,"version":"build-2803163510"},"reference-count":64,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>The integration of biosimilars into pediatric healthcare represents a significant evolution in treatment accessibility and cost\u2010effectiveness. Biosimilars\u2014biological products highly similar to already approved biologics, have emerged as promising alternatives for managing chronic and rare pediatric conditions, including inflammatory bowel disease, juvenile idiopathic arthritis, psoriasis, asthma, lupus nephritis, and growth hormone deficiencies. Despite regulatory, clinical, and societal challenges, current data suggest biosimilars demonstrate comparable safety, efficacy, and immunogenicity profiles to their originator products. The review consolidates findings from recent clinical trials, real\u2010world data, and regulatory landscapes across the US and EU, emphasizing the growing role of biosimilars in pediatric pharmacotherapy. It also explores future directions in biosimilar development, highlighting the need for improved pediatric\u2010specific research, regulatory harmonization, and stakeholder education to ensure wider adoption and optimized outcomes in children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A structured literature search of PubMed, Scopus, Web of Science, and Google Scholar (2003\u2013March 2026) identified English\u2010language studies on pediatric biosimilars. Relevant clinical, regulatory, and review articles were thematically synthesized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In pediatric patients with chronic conditions such as inflammatory bowel disease and rheumatologic disorders, biosimilars like infliximab and adalimumab offer efficacy and safety comparable to originator biologics, while lowering treatment costs. Economic analyses demonstrate that biosimilars are typically 15%\u201345% cheaper than reference products in Europe, and in some markets up to 85% lower, improving affordability and access to treatment in pediatric populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Biosimilars have a great deal of promise to improve therapeutic access and lower medical expenses associated with pediatric care. However, to maximize results and guarantee therapeutic fairness in pediatric medicine, broader adoption necessitates increased age\u2010specific clinical trials, harmonized regulations, better training for healthcare providers, and increased stakeholder trust.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hsr2.72426","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:21:06Z","timestamp":1777537266000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7243-4791","authenticated-orcid":false,"given":"Zubaier","family":"Ahmed","sequence":"first","affiliation":[{"name":"School of Pharmacy BRAC University Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasfiah Tasnim","family":"Maha","sequence":"additional","affiliation":[{"name":"School of Pharmacy BRAC University Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Nowsher","sequence":"additional","affiliation":[{"name":"Department of Pharmacy North South University Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasima","family":"Taslim","sequence":"additional","affiliation":[{"name":"School of Pharmacy BRAC University Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6087-0425","authenticated-orcid":false,"family":"Fatema\u2010Tuz\u2010Zohora","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Asia Pacific Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Sharmin","sequence":"additional","affiliation":[{"name":"School of Pharmacy BRAC University Dhaka Bangladesh"},{"name":"Department of Pharmaceutical Chemistry Universiti Teknologi MARA  Selangor Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasina","family":"Yasmin","sequence":"additional","affiliation":[{"name":"School of Pharmacy BRAC University Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051010-162644"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1179"},{"key":"e_1_2_14_4_1","unstructured":"T.Perry \u201cBiosimilars or Biologics: What's the Difference? \u201d Therapeutics Letter [Internet] published 2019 https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK598450\/."},{"issue":"4","key":"e_1_2_14_5_1","first-page":"24","article-title":"Defining the Difference: What Makes Biologics Unique","volume":"1","author":"Morrow T.","year":"2004","journal-title":"Biotechnology Healthcare"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/sci6010009"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.26438"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01472-1"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S367032"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-024-00873-4"},{"key":"e_1_2_14_11_1","unstructured":"\u201cBiosimilar Growth Hormone Reveals Efficacy Safety in Real\u2010World Pediatric PATRO Study [Internet] \u201dhttps:\/\/www.centerforbiosimilars.com\/view\/biosimilar-growth-hormone-reveals-efficacy-safety-in-real-world-pediatric-patro-study."},{"key":"e_1_2_14_12_1","unstructured":"\u201cDeveloping BIOSIMILARS. Process Qual Stand AMGEN Biosimilars [Internet] \u201dhttps:\/\/www.amgenbiosimilars.com\/."},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16030321"},{"key":"e_1_2_14_14_1","volume-title":"William & Mary Business Law Review","author":"Koballa K. E.","year":"2018"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-020-00377-2"},{"issue":"3","key":"e_1_2_14_16_1","first-page":"139","article-title":"Pediatric Medicine Development: An Overview and Comparison of Regulatory Processes in the European Union and United States","volume":"176","author":"Dobromir Penkov M. D.","year":"2017","journal-title":"Physiology and Behavior"},{"key":"e_1_2_14_17_1","unstructured":"\u201cFood and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Pediatric Drug Development Under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act: Scientific Considerations Guidance for Industry. Draft Guidance \u201d May 2023 1\u201319 https:\/\/www.fda.gov\/media\/168202\/download."},{"key":"e_1_2_14_18_1","unstructured":"\u201cEC. Regulation (EC) No 1902\/2006 of the European Parliament and of the Council of 20 December 2006 Amending Regulation 1901\/2006 on Medicinal Products for Paediatric Use Official Journal of European Union [Internet] \u201d 2006 (I: 378\/20):20\u20131 http:\/\/ec.europa.eu\/health\/files\/eudralex\/vol-1\/reg_2006_1902\/reg_2006_1902_en.pdf."},{"issue":"4","key":"e_1_2_14_19_1","first-page":"619","article-title":"Rituximab in the Treatment of Non\u2010Hodgkin's Lymphoma","volume":"2","author":"Hauptrock B.","year":"2008","journal-title":"Biologics: Targets & Therapy"},{"key":"e_1_2_14_20_1","unstructured":"M. J.FieldandT. F.Boat \u201cSafe and Effective Medicines for Children: Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act \u201d October 13 2012 1\u2013408 https:\/\/pubmed.ncbi.nlm.nih.gov\/24872968\/."},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17165800"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i35.4021"},{"key":"e_1_2_14_23_1","unstructured":"\u201cAdalimumab and Biosimilars Side\u2010by\u2010Side Comparison April 2024 https:\/\/vizientinc-delivery.sitecorecontenthub.cloud\/api\/public\/content\/1275e40ca4af48be9b9dd77ff7f18e06."},{"issue":"2","key":"e_1_2_14_24_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/01.NAJ.0000820544.63258.6b","article-title":"Drug Wins Designation as a Biosimilar Product to Humira","volume":"122","author":"Aschenbrenner D. S.","year":"2022","journal-title":"AJN, American Journal of Nursing"},{"key":"e_1_2_14_25_1","unstructured":"\u201cFDA Approves New Pfizer Biosimilar | Pfizer [Internet] \u201d accessed June 14 2025 https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/fda_approves_new_pfizer_biosimilar."},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.5937\/pomc20-49625"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.24953\/turkjped.2019.02.005"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-013-9814-8"},{"key":"e_1_2_14_29_1","article-title":"Pyzchiva (ustekinumab\u2010ttwe): A New Biosimilar for Psoriasis","author":"Lindecker B.","journal-title":"Annals of Pharmacotherapy"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583617"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S124476"},{"key":"e_1_2_14_32_1","doi-asserted-by":"crossref","unstructured":"M.W. Report \u201cAsthma Surveillance\u2014United States 2006\u20132018 \u201d 70 (5): 2021 2006\u201318.","DOI":"10.15585\/mmwr.ss7005a1"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.5888\/pcd11.140139"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020321"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.01.002"},{"key":"e_1_2_14_36_1","volume-title":"StatPearls [Internet]","author":"Kumar C.","year":"2023"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.03.002"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-019-0602-5"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1425906"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000003786"},{"key":"e_1_2_14_41_1","volume-title":"StatPearls [Internet]","author":"Musa R.","year":"2025"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1590\/2175-8239-jbn-2018-0097"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04686-1"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11051503"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-019-0365-y"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1159\/000082102"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.03.041"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002141"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001643"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2025.2453516"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-eular.4477"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10864"},{"key":"e_1_2_14_53_1","unstructured":"\u201cFDA aPproves Ustekinumab\u2010ttwe as Biosimilar for Pediatric Plaque Psoriasis Active Psoriatic Arthritis [Internet] \u201dhttps:\/\/www.contemporarypediatrics.com\/view\/fda-approves-ustekinumab-ttwe-as-biosimilar-for-pediatric-plaque-psoriasis-active-psoriatic-arthritis."},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15679"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S440009"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11325"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231190827"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-024-00659-0"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2019-318676"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2025.102606"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.3390\/children12050656"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.156983.1"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S514115"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv233"},{"issue":"5","key":"e_1_2_14_65_1","first-page":"1685","article-title":"A Comprehensive Review on Biosimilars","volume":"2","author":"Gaidhani K. A.","year":"2021","journal-title":"SJIF Journal"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.72426","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hsr2.72426","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.72426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:57:23Z","timestamp":1788343043000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.72426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/hsr2.72426"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.72426","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"2025-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72426"}}